HGF and neoplasm: Taken together, these results imply that the inhibition of bone loss in tumour-bearing mice treated with ARQ-197 is a consequence of tumour load reduction, and the prevention of HGF-induced inhibition of osteoblasts, rather than a direct bone anabolic effect.